Cargando…
The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevert...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433627/ https://www.ncbi.nlm.nih.gov/pubmed/28410288 http://dx.doi.org/10.1097/MNM.0000000000000674 |
_version_ | 1783236885793996800 |
---|---|
author | Uyama, Naoto Otsuka, Hideki Shinya, Takayoshi Otomi, Yoichi Harada, Masafumi Sako, Wataru Izumi, Yuishin Kaji, Ryuji Watanabe, Yuya Takashi, Satoru Kunikane, Yamato |
author_facet | Uyama, Naoto Otsuka, Hideki Shinya, Takayoshi Otomi, Yoichi Harada, Masafumi Sako, Wataru Izumi, Yuishin Kaji, Ryuji Watanabe, Yuya Takashi, Satoru Kunikane, Yamato |
author_sort | Uyama, Naoto |
collection | PubMed |
description | OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevertheless, these modalities are often insufficient for achieving a definite diagnosis. The aims of this study were to evaluate the diagnostic accuracy of the combination of these tools. MATERIALS AND METHODS: The SPECT radiotracers [(123)I]-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)-nortropane (FP-CIT) and meta-[(123)I]-iodobenzylguanidine (MIBG) were used to research presynaptic dopaminergic projections (DAT SPECT) and myocardial adrenergic innervation (MIBG scintigraphy), respectively. PD patients (n=15; age: 61.5±13.6 years) and non-PD patients (n=19; age: 62.6±14.2 years) who underwent both tests were enrolled in this study. Receiver-operating characteristic analyses were used to set the cutoff values of the specific binding ratio in DAT SPECT and the heart to mediastinum ratio in delayed scan in MIBG scintigraphy for differentiating PD from non-PD. We calculated the sensitivity, specificity, and test accuracy of the individual methods and also the combination of these two modalities. RESULTS: When DAT SPECT and MIBG scintigraphy were used individually, they showed mild accuracy in differentiating PD from non-PD (DAT, 67.6%; MIBG, 67.6%). The combination of the two approaches using cutoff values of less than 3.24 for the specific binding ratio and less than 2.745 for the delayed heart to mediastinum ratio enabled more accurate differentiation between PD and non-PD. The accuracy of these indices in distinguishing PD from non-PD was 79.4%. CONCLUSION: These results suggested that the combination of DAT SPECT and MIBG scintigraphy may improve the diagnostic accuracy in differentiating PD from non-PD. |
format | Online Article Text |
id | pubmed-5433627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-54336272017-05-23 The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes Uyama, Naoto Otsuka, Hideki Shinya, Takayoshi Otomi, Yoichi Harada, Masafumi Sako, Wataru Izumi, Yuishin Kaji, Ryuji Watanabe, Yuya Takashi, Satoru Kunikane, Yamato Nucl Med Commun Original Articles OBJECTIVE: Molecular imaging of nigrostriatal dopamine transporters (DAT) and sympathetic cardiac innervation with single-photon emission computed tomography (SPECT) are useful tools for differentiating idiopathic Parkinson disease (PD) from other degenerative parkinsonian syndromes (non-PD). Nevertheless, these modalities are often insufficient for achieving a definite diagnosis. The aims of this study were to evaluate the diagnostic accuracy of the combination of these tools. MATERIALS AND METHODS: The SPECT radiotracers [(123)I]-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)-nortropane (FP-CIT) and meta-[(123)I]-iodobenzylguanidine (MIBG) were used to research presynaptic dopaminergic projections (DAT SPECT) and myocardial adrenergic innervation (MIBG scintigraphy), respectively. PD patients (n=15; age: 61.5±13.6 years) and non-PD patients (n=19; age: 62.6±14.2 years) who underwent both tests were enrolled in this study. Receiver-operating characteristic analyses were used to set the cutoff values of the specific binding ratio in DAT SPECT and the heart to mediastinum ratio in delayed scan in MIBG scintigraphy for differentiating PD from non-PD. We calculated the sensitivity, specificity, and test accuracy of the individual methods and also the combination of these two modalities. RESULTS: When DAT SPECT and MIBG scintigraphy were used individually, they showed mild accuracy in differentiating PD from non-PD (DAT, 67.6%; MIBG, 67.6%). The combination of the two approaches using cutoff values of less than 3.24 for the specific binding ratio and less than 2.745 for the delayed heart to mediastinum ratio enabled more accurate differentiation between PD and non-PD. The accuracy of these indices in distinguishing PD from non-PD was 79.4%. CONCLUSION: These results suggested that the combination of DAT SPECT and MIBG scintigraphy may improve the diagnostic accuracy in differentiating PD from non-PD. Lippincott Williams & Wilkins 2017-06 2017-04-18 /pmc/articles/PMC5433627/ /pubmed/28410288 http://dx.doi.org/10.1097/MNM.0000000000000674 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CreativeCommonsAttribution-NonCommercial-NoDerivativesLicense4.0) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Articles Uyama, Naoto Otsuka, Hideki Shinya, Takayoshi Otomi, Yoichi Harada, Masafumi Sako, Wataru Izumi, Yuishin Kaji, Ryuji Watanabe, Yuya Takashi, Satoru Kunikane, Yamato The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title | The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title_full | The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title_fullStr | The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title_full_unstemmed | The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title_short | The utility of the combination of a SPECT study with [(123)I]-FP-CIT of dopamine transporters and [(123)I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes |
title_sort | utility of the combination of a spect study with [(123)i]-fp-cit of dopamine transporters and [(123)i]-mibg myocardial scintigraphy in differentiating parkinson disease from other degenerative parkinsonian syndromes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433627/ https://www.ncbi.nlm.nih.gov/pubmed/28410288 http://dx.doi.org/10.1097/MNM.0000000000000674 |
work_keys_str_mv | AT uyamanaoto theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT otsukahideki theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT shinyatakayoshi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT otomiyoichi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT haradamasafumi theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT sakowataru theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT izumiyuishin theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT kajiryuji theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT watanabeyuya theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT takashisatoru theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT kunikaneyamato theutilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT uyamanaoto utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT otsukahideki utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT shinyatakayoshi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT otomiyoichi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT haradamasafumi utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT sakowataru utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT izumiyuishin utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT kajiryuji utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT watanabeyuya utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT takashisatoru utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes AT kunikaneyamato utilityofthecombinationofaspectstudywith123ifpcitofdopaminetransportersand123imibgmyocardialscintigraphyindifferentiatingparkinsondiseasefromotherdegenerativeparkinsoniansyndromes |